Medizinportal Arztsuche Apothekensuche KliniksucheHealth Provider Directory - Health in Germany - english-language-version
Home DocSearch ClinicSearch HealthSites

News

2006-01-03:
AstraZeneca Submits sNDA for SEROQUEL( R ) for Bipolar Depression Treatment
Alderley Park, England ( PRN/ots ) - - Filing Seeks Approval of SEROQUEL as a Monotherapy Treatment for Bipolar Depression AstraZeneca today announced submission of a supplemental New Drug Application ( sNDA ) to the US Food and Drug Administration ( FDA ) to seek approval for a new (...)
2006-03-19:
CBMI' s Executive Director, Dave McComiskey is Calling Upon World Leaders to Help With the Worst Drought in Decades in the Horn of Africa
Toronto, Canada ( PRN/ots ) - There are 18 million undernourished people and 7.5 million at risk of starvation and after six years of drought, crops across East Africa have failed again. National governments, local authorities and the United Nations need to respond in a (...)
2007-04-19:
ProBioGen, Germany and Minapharm, Egypt enter into development and co - promotion agreements
Berlin ( na Originaltextservice ) - ProBioGen and Minapharm jointly announced today that they have entered into two separate agreements to develop two therapeutic proteins, one exclusively for Minapharm and another second generation biopharmaceutical product for co - promotion. In the first agreement, ProBioGen will (...)
2006-11-03:
SemBioSys Announces Successful Outcome of Personal Care Product Appeal Proceedings at the European Patent Office
Calgary, Canada, November 3 ( PRN/ots ) - - Canadian Biotechnology Company's Intellectual Property Position Strengthened by Decision TSX symbol: SBS SemBioSys Genetics Inc. ( TSX: SBS ), a biotechnology company developing a broad pipeline of protein - based pharmaceuticals and non - pharmaceutical products today announced that it (...)
2007-02-06:
Abbott to Initiate First Study to Evaluate XIENCE( TM ) V Everolimus Eluting Coronary Stent System in Treatment of Women With Cardiovascular Disease
Abbott Park, Illinois ( PRN/ots ) - - First - of - its - Kind Study Designed to Learn More About Cardiovascular Disease in Women Abbott today announced plans to initiate the world's first drug - eluting stent clinical trial solely in women. The SPIRIT WOMEN trial will aim (...)
2010-11-20:
Good News for Kidney Patients: World's Largest Kidney Disease Trial Shows Big Benefits From Reducing Cholesterol
Denver, November 20 ( PRN/ots ) - Around a quarter of all heart attacks, strokes, and operations to open blocked arteries could be avoided in people with chronic kidney disease by using the combination of ezetimibe and simvastatin to lower blood cholesterol levels. That's the conclusion (...)
2009-07-02:
FDA Approves Multaq( R ) for Patients With Atrial Fibrillation or Atrial Flutter
Paris ( PRN/ots ) - - Multaq( R ) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial Flutter - U.S Commercial Launch Planned for the Summer of 2009 Sanofi - aventis ( EURONEXT: SAN and NYSE: SNY ) announced today that the U.S. Food (...)
2006-03-17:
Advisory - Isotechnika to Announce Clinical Data From Phase III Psoriasis Trial
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. will announce preliminary 48 week clinical trial data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247, on Monday, March 20th at 8:00 a.m. EST/6:00 a.m. MST. Management will (...)
2007-09-25:
Siemens Medical Solutions Diagnostics Launches the DCA Vantage Analyzer for Point - of - care Diabetes Management
Tarrytown, New York ( PRN/ots ) - - Advanced Network - Ready Diabetes Analysis for Better Patient Management Siemens Medical Solutions Diagnostics ( www.siemens.com/diagnostics ) today announced the launch of the DCA Vantage( TM ) Analyzer, a point - of - care ( POC ) diabetes patient management platform providing glycosylated hemoglobin ( HbA1c ), Microalbumin/Creatinine (...)
2007-06-04:
Colorectal Cancer Patients Treated With XELOX Spend Over 160 Fewer Hours Receiving Intravenous Treatment
Chicago ( PRN/ots ) - - Oral Xeloda( R ) Combination Effective and Time - Saving Data presented today at the American Society of Clinical Oncology Annual Meeting ( ASCO ) in Chicago showed that not only is XELOX as effective as intravenous ( i.v. ) drug regimens, but that colorectal cancer (...)
2008-09-16:
New Data Confirms Avastin ( R ) as the Only Biologic to Demonstrate Overall Survival When Used First - Line in Metastatic Colorectal Cancer Patients With K - RAS ( Wild - Type ) Gene Status
Basel, Switzerland ( PRN/ots ) - Avastin ( bevacizumab ) remains the only biologic to provide overall survival ( OS ) benefit when used as first - line treatment in combination with chemotherapy for patients with K - Ras wild type metastatic colorectal cancer ( mCRC ). Avastin's strong position was confirmed today following new (...)
2009-06-23:
New Educational Initiative Urges People With Rheumatoid Arthritis ( RA ) to Dedicate One Day so That They May Make a Lasting Difference to How They Live With Their Condition
Maidenhead, England ( PRN/ots ) - - My Day for RA Launches Across Europe Today: A Novel 'Goal - Centred' Patient Programme Recognising that rheumatoid arthritis ( RA ) can cause deformity, disability and loss of independence without effective management - My Day for RA, a new educational programme, (...)
2009-12-17:
FDA Broadens Clearance for Agendia's MammaPrint( R )
Huntington Beach, California and Amsterdam ( PRN/ots ) - - Agendia, a world leader in molecular cancer diagnostics, announced today that the US Food and Drug Administration ( FDA ) cleared its MammaPrint breast cancer recurrence test for all ages. MammaPrint is the only FDA - cleared breast cancer (...)
2008-03-26:
SemBioSys Initiates Toxicology Study for Safflower - Produced Insulin
Calgary, Canada ( PRN/ots ) - - Initiation of Study Puts Company on Track for Phase I/II Trial SemBioSys Genetics Inc. ( TSX: SBS ), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it has initiated (...)
2009-06-23:
Abbott Receives CE Mark for Company's Next - Generation XIENCE PRIME( TM ) Drug Eluting Stent, Advancing Leadership Position
Abbott Park, Illinois ( PRN/ots ) - - Broad Size Matrix of XIENCE PRIME to be Launched in Europe in the Third Quarter Abbott announced today that it has received CE Mark ( Conformite Europeenne ) for its next - generation XIENCE PRIME( TM ) Everolimus Eluting Coronary Stent System (...)
2009-01-29:
AGA Medical Corporation Begins Proceedings Against Occlutech to Recover Damages
Minneapolis ( PRN/ots ) - AGA Medical Corporation ( AGA ) today announced that, following its previously announced favorable patent infringement final ruling by the German court of appeals over Occlutech GmbH of Jena, Germany ( Occlutech ), it has calculated and notified Occlutech of the amount of damages (...)
2006-03-17:
Significant Long Term Efficacy of Protelos( R ) ( Strontium Ranelate ) Confirmed
Vienna, Austria ( PRN/ots ) - - New Data Demonstrate "Unique", Five Year Anti - Osteoporotic Efficacy Against Both Vertebral and Non - Vertebral Fractures New five year data presented at the 6th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis ( ECCEO 6 ) meeting (...)
2007-04-25:
Tarceva( R ) Extends Life of Patients with Pancreatic Cancer
Basel, Switzerland ( PRN/ots ) - - Newly published results show significant improvement in survival when innovative, oral cancer drug Tarceva is added to chemotherapy New results published by the Journal of Clinical Oncology show that adding Tarceva ( erlotinib ) to gemcitabine chemotherapy significantly improves survival (...)
2005-04-21:
Genizon Biosciences Announces Major Milestone in Identifying Genes Involved in Psoriasis
Montreal, Canada ( PRN/ots ) - Genizon BioSciences today announced the confirmation of a previously reported disease - gene location, PSORS1, as well as the identification of more than 10 new regions strongly associated with psoriasis, each containing only a limited number of genes. The company will (...)
2011-03-23:
Treatment With Prolia( R ) ( denosumab ) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
Thousand Oaks, California ( PRN/ots ) - Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia( R ) ( denosumab ) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis. Adherence to treatment, which includes both (...)
2008-12-04:
European Commission Approval of New Indication for Roche's Pegasys( R ) ( peginterferon alfa - 2a ) Offers Hepatitis C Patients a Second Chance for a Cure
Basel ( PRN/ots ) - - Pegasys is the First and Only Pegylated Interferon to be Approved for Treatment of up to 72 Weeks in Treatment - Experienced Patients Roche announced today that the European Commission has approved Pegasys( R ) ( peginterferon alfa - 2a ( 0 KD ) ) plus Copegus( R ) (...)
2006-08-02:
Medify Solutions Limited ( Pink Sheets MFYS ) - Statement
Gateshead, England ( PRN/ots ) - Due to the number of product sales enquiries from UK based NHS GP practices, Medify Solutions Limited would like to clarify the product availability situation. The first production release of Medify Remote is scheduled to be utilised at Doncaster Central (...)
2009-06-03:
Investigational Cancer Drug BSI - 201 Showed Clinical Benefit in 62 Prozent of Patients with Triple - Negative Metastatic Breast Cancer and Significantly Prolonged Survival
Paris and Brisbane, California ( PRN/ots ) - - Data Highlighted in Plenary Session of 2009 American Society of Clinical Oncology Annual Meeting Sanofi - aventis ( EURONEXT: SAN and NYSE: SNY ) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2 (...)
2011-03-29:
Institut Pasteur Shanghai Announces the Creation of its Global Biotech Accelerator Advance BioChina
Biovision, Lyon, France ( PRN/ots ) - Institut Pasteur of Shanghai announces today the creation of its global biotech accelerator company Advance BioChina. Advance BioChina is an R&D - focused for - profit organization that positions itself as the gateway to China for global biotech companies. Advance BioChina (...)
2008-07-08:
Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7 - Valent Pneumococcal Conjugate Vaccine ( PCV7 ) in Their Immunization Schedules
Maidenhead, England ( PRN/ots ) - - PREVENAR Vaccine to Help Protect Children Against the Leading Vaccine - Preventable Cause of Death in Young Children Wyeth applauds the countries of Cyprus, Hungary, the Kingdom of Bahrain, Republic of Ireland, Slovak Republic and Sweden for announcing their (...)
2009-07-14:
Wyeth's Prevenar 13* Receives First Approval
Collegeville, Pennsylvania ( PRN/ots ) - - Chile Grants First Approval of Prevenar 13 for the Prevention of Pneumococcal Disease in Infants and Children - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), announced today that the Chilean Ministry of Health, MINSAL ( Ministerio de Salud ), (...)
2008-04-29:
Journalist Invitation - International Media Webcast
Ingelheim, Germany ( PRN/ots ) - The science of sexual desire No doubt you've written about it before: Sex - an ever - present topic in newspapers and magazines. Yet, despite the genuine interest in sex, little focus is given to the science behind it (...)
2009-03-10:
Chronic Kidney Disease and Hypertension: Twin Challenges for 21st Century Europe
Strasbourg, France ( PRN/ots ) - - Meeting at European Parliament relays stark message and calls for action to support early identification and treatment of CKD, especially among patients at greatest risk The European Kidney Health Alliance ( EKHA ) and World Kidney Day ( WKD ) organisations today (...)
2010-12-08:
European Approval for SPRYCEL( R ) ( dasatinib ) in Adult Patients With Newly Diagnosed CML: First New Approved Treatment in the E.U. With Superior Efficacy vs. Imatinib Since 2001
Paris ( PRN/ots ) - Bristol - Myers Squibb today announced that SPRYCEL( R ) ( dasatinib ) 100mg once daily received Marketing Authorization from the European Commission for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive ( Ph+ ) Chronic Myelogenous Leukaemia in Chronic Phase ( CML - CP ). Sprycel is the (...)
2011-04-12:
Pieris and Daiichi Sankyo Sign Therapeutic Collaboration to Develop Anticalin( R ) Therapeutics
Freising, Germany ( na Originaltextservice ) - Pieris AG announced today the signature of a collaboration and license agreement with Daiichi Sankyo Company Limited ( hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568 ), under which Pieris will apply its proprietary Anticalin scaffold technology (...)
2008-05-31:
Catumaxomab, Representing a New Generation of Antibodies, Proved Efficient and Safe in Malignant Ascites / Data presented at 44th annual ASCO congress, Chicago, USA
München, Deutschland und Chicago, USA ( na Originaltextservice ) - Treatment with the trifunctional antibody catumaxomab significantly prolongs puncture - free survival in patients with malignant ascites, according to the results from a Phase II/III trial presented at the 44th American Society of Clinical (...)
2009-01-06:
MedImmune Submits Marketing Authorisation Application in European Union for Intranasal Vaccine to Prevent Seasonal Influenza
Nijmegen, The Netherlands ( PRN/ots ) - MedImmune, the global biologics unit of AstraZeneca, announced today that it has submitted a Marketing Authorisation Application ( MAA ) for its nasal spray live attenuated influenza vaccine ( LAIV ), which is now being reviewed by the European Medicines Agency (...)
2008-06-18:
MICARDIS( R ) - Based Regimens Help More Patients Achieve Their Blood Pressure Goals
Berlin ( PRN/ots ) - - For non - US Healthcare Media and non - UK Healthcare Media - New Studies Show Benefits of MICARDIS( R ) ( Telmisartan ) in Combination With Amlodipine and Hydrochlorothiazide The results of two new studies of MICARDIS( R ) ( telmisartan ) in free combination with amlodipine or (...)
2008-04-22:
Dosing for RVX - 208 Phase 1a Clinical Study Completed
Calgary, Canada ( PRN/ots ) - - Phase 1a Study Objectives Were Met - TSX Exchange Symbol: RVX Resverlogix Corp. ( "Resverlogix" or the "Company" ) ( TSX:RVX ) announced today that it has completed dosing of its Phase 1a safety, tolerability and pharmacokinetics study for its lead (...)
2008-05-29:
Drug - Eluting Coronary Stents Utilizing Isotechnika's Lead Drug Receive Approval to Enter Clinical Trials
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. announced today that voclosporin is positioned to enter a Phase 1 clinical trial as the drug utilized in the CINATRA( TM ) Drug Coated Coronary Stent system developed by the Company's partner, Atrium Medical Corporation. Atrium has received approval from (...)
2006-09-03:
New Study Shows Benefits of Coversyl ( R ) ( Perindopril ) in Elderly With Chronic Heart Failure
Barcelona, Spain ( PRN/ots ) - - Coversyl( R ) in PEP - CHF Trial, is the First Agent to Demonstrate Clinical Benefits in Elderly Heart Failure Patients With Diastolic Dysfunction The ACE inhibitor Coversyl( R ) ( perindopril ) provides a number of clinical benefits to elderly people with chronic heart (...)
2009-07-30:
Eli Lilly & Company and ScinoPharm Taiwan Ltd. Announce Settlement of Gemcitabine Litigation
Tainan, Taiwan ( PRN/ots ) - Eli Lilly & Company ( "Lilly" ) and ScinoPharm Taiwan Ltd. ( "ScinoPharm" ) announced today that they have reached an amicable resolution of all ongoing patent litigations between the companies relating to ScinoPharm's manufacture and sale of gemcitabine hydrochloride around the world. (...)
2010-04-20:
Urology and Transplantation Will Drive Future Growth as Astellas Begins Move into Oncology
London, April 20, 2010 ( PRN/ots ) - Today, on the fifth anniversary since its formation, Astellas Pharma Europe has confirmed that it will continue its emphasis on transplantation and urology while moving towards a new vision to build a strong presence in oncology. Astellas has (...)
2010-01-05:
New Analysis Showed Efient( R ) Cost - Effective Compared with Clopidogrel for Patients with Acute Coronary Syndromes Undergoing PCI
Tokyo and Indianapolis ( PRN/ots ) - Results from a health economic substudy of the TRITON - TIMI 38 clinical trial showed that among patients with acute coronary syndrome ( ACS ) managed with percutaneous coronary intervention ( PCI ), including stenting, treatment with Efient( R ) ( prasugrel ) compared with branded clopidogrel ( Plavix( R ) ) was (...)
2007-06-11:
Organon's Sugammadex Demonstrated a 9 - 12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
Oss, The Netherlands ( PRN/ots ) - Sugammadex - the novel selective relaxant binding agent ( SRBA ) being developed by Organon, the human healthcare business unit of Akzo Nobel - demonstrated in a Phase III pivotal trial a 9 - 12 times faster reversal of neuromuscular blockade as compared to (...)
2010-12-13:
Institut Mérieux Strengthens its Commitment to Medicine and Global Public Health
Paris ( PRN/ots ) - Institut Mérieux strengthens its commitment to medicine and global public health via an ambitious innovation policy, the structuring of a food safety/nutrition hub and the creation of a company dedicated to diagnostics in developing countries. One year after reinstating the (...)
2007-06-18:
New Study Shows That telmisartan has Greater Renoprotective Potential Than losartan in Hypertensive Patients With Type 2 Diabetes
Milan, Italy ( PRN/ots ) - - For non - US Healthcare Media Today AMADEO, one of the first studies to compare the protective potential of two angiotensin receptor blockers in hypertensive patients with diabetic nephropathy, was presented at the European Society of Hypertension, Milan. The (...)
2010-11-10:
Inaccurate Reporting on Recent Omega - 3 DHA Alzheimer's Study Reveals Misrepresentation by Media
Dartmouth, Nova Scotia, November 10 ( PRN/ots ) - Several media outlets published articles last week suggesting that Omega - 3 fish oil supplements fail to show positive results for Alzheimer's patients. This reporting by media outlets came after the Journal of the American Medical Association ( JAMA ) (...)
2007-08-24:
AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Minneapolis ( PRN/ots ) - AGA Medical Corporation ( "AGA" ) announced today that it has received U.S. Food and Drug Administration ( FDA ) and European CE Mark approvals for the AMPLATZER Vascular Plug II ( "vascular plug II" ). The AMPLATZER Vascular Plug II expands the AGA (...)
2005-09-07:
New International Treatment Guidelines Verify Crucial Role of 'Arimidex'( TM ) ( Anastrozole ) for Postmenopausal Women With Early Breast Cancer
Macclesfield, England ( PRN/ots ) - Today, new guidelines from the prestigious St. Gallen 'International Consensus Conference on the Primary Therapy of Early Breast Cancer' were released ahead of publication on the Annals of Oncology website( 1 ). For the first time, the St. Gallen consensus panel has (...)
2008-09-15:
South Africa Begins Introduction of PREVENAR into Childhood Immunization Program
Collegeville, Pennsylvania ( PRN/ots ) - - First African Nation Plans to Phase in Routine Vaccination Program Against Pneumococcal Disease for Infants and Young Children - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), today announced that South Africa has initiated an immunization program against (...)
2008-09-23:
New Data Supports the Safety Record of ENBREL( R ) as a Continuous Therapy in Children and Adolescents With Juvenile Idiopathic Arthritis
Maidenhead, England ( PRN/ots ) - - Data Represents More than 800 Patient Years of Experience Wyeth today announced study results from last week's 15th Paediatric Rheumatology European Congress ( PRES ) in London which highlight the safety record of etanercept ( ENBREL( R ) ) as a continuous therapy in (...)
2006-08-03:
Global Definition of GERD Set to Transform Current Clinical Practice
Madison, Wisconsin ( PRN/ots ) - An international consensus group of the world's leading experts in gastroenterology today published the Montreal Definition( x ) of gastroesophageal reflux disease ( GERD ), in the August issue of the American Journal of Gastroenterology. The global consensus definition is intended to provide a universal (...)
2008-04-25:
Data Suggests Promising Overall Survival and Progression - Free Survival With VARGATEF( TM ) ( BIBF 1120 )
Ingelheim, Germany ( PRN/ots ) - - For non - US Healthcare Media - Abstract # 163O. von Pawel. Proffered Papers 6 - Advanced NSCLC - Latest Phase II Data for Boehringer Ingelheim's New Cancer Drug in Development Presented Monotherapy treatment with the triple angiokinase inhibitor( 1 ) BIBF 1120 (...)

back... 1 2 3 4 5 6 7 8 9 10 11 more...



» German Health-Sites

Medical and health related Websites from Germany

Alternative Medicine
Beauty and Wellness
Manufacturers of Medical Equipment
Biotechnology
International
Databases
German Doctors Worldwide
German Medicine and Patient Transfer
Special Diagnoses
Acne
Cancer
Diabetes
Nutrition and Diet
Family
Fitness and Sports
Forums
Womens Health
Genetics
Health-Marketing
Dating
Health Insurance
Other Insurances
Literature and Publishers
Newspaper / Magazines
Organizations
Care
Portals and Directories
Pharmacies
Portals and Directories Dental Medicine
Search
Psyche
Public Health
Governmental Links
Guides
Regional
Baden-Wuerttemberg
Bavaria
Berlin
North Rhine-Westphalia
Travel Medicine
Self-Help
AIDS
Alcoholism
Alzheimer
Medical malpractice
Visually Impaired
Seminar
Seniors / 50+
Seniors / Living
Shopping
Medical Technology
Children-, Youth- and Social Work
Scholastics
Accommodation
Organization
Mixed


© 2003-2008 med-kolleg.de Health Provider Directory
Clinics and Physicians
Berlin, Germany Freitag, 6.12.2019.
Sitemap (Sitemap German) Imprint Press (German)
Ärzteverzeichnis Klinikverzeichnis Apothekenverzeichnis Ärztesuche
 Thu, 05 Dec 2019 12:17:23 GMT
Werben im Gesundheitssektor / Medizin

Health Provider Directory

Medizin und Gesundheit - Arztsuche Kliniksuche Apothekensuche
Gesundheitsportal